STOMP: Selinexor + Pd - Capsule Summary Slidesets - Myeloma - 2019 ASH Annual Meeting - Oncology - Clinical Care Options
Selinexor: First Global Approval | SpringerLink
Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable - Clinical Lymphoma, Myeloma and Leukemia
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial - The Lancet
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials | Leukemia
Clinical trials of selinexor and eltanexor in hematological malignancies | Download Scientific Diagram
Overview of clinical trials involving selinexor in childhood cancer. | Download Scientific Diagram
Selinexor COVID-19 trial | Norton Healthcare Louisville, Ky.
Single Cell RNA Sequencing in Patients Enrolled in a Selinexor Clinical Trial Reveals Overexpression of Alternative Nuclear Export Pathways Associated with Resistance to Selinexor in Refractory Multiple Myeloma - ScienceDirect
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial - The Lancet
Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma
Multiple Myeloma Support + Trials
Understanding the FDA approved New Drug, Selinexor and its Use in Multiple Myeloma - YouTube
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial - The Lancet Haematology
Clinical Outcomes in Patients with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study
Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma - ScienceDirect
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials | Leukemia
Donna's Switch to Selinexor and MM Clinical Trial Treatment
Selinexor - Wikipedia
EX-99.1
Selinexor Clinical Trials | Int'l Myeloma Foundation
Selinexor for Amyloidosis Clinical Trial 2022 | Power
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients | British Journal of Cancer
